FDA rejection and regulatory status Development timeline: 2000s: Developed for Parkinson's/Alzheimer's 2008: Phase 2 obesity trials (successful) 2010: Phase 3 trials initiated 2010: Development halted due to safety concerns 2012: FDA rejected obesity indication Present: No approved indication anywhere Why FDA rejected: Cardiovascular safety concerns primary reason Increased heart rate and blood pressure Risk-benefit ratio unfavorable Safer alternatives available ( GLP-1 agonists ) Development company abandoned pursuit No current path to approval Regulatory status by country: Current legal classification: Not a controlled substance (not scheduled) Not approved for any human use Sold as "research chemical" only "Not for human consumption" labels Legal gray area (enforcement rare) See are peptides legal guide at SeekPeptides
Price MB, Jelesko J, Okumoto S (2012) Glutamate receptor homologs in plants: functions and evolutionary origins
Potent macrocyclic inhibitors of insulin-regulated aminopeptidase (IRAP) by olefin ring-closing metathesis
It promotes healing by enhancing blood flow, reducing inflammation, and boosting collagen synthesis
Park S, Chen J
It is worth emphasizing, though, that this study was conducted in subjects already engaged in regular resistance training (males, ages 18-35, who performed resistance training at least three times weekly for a year), so we cannot necessarily extrapolate the results to individuals who do not participate in this kind of activity
